Press Releases

Year None 2026 2025 2024 2023

November 12, 2026

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

November 10, 2026

Black Diamond Therapeutics Announces Positive Updated Silevertinib Phase 2 Results, FDA Feedback Supporting a Clear Path to Potential Registration in 1L EGFR-NCM NSCLC, and Provides Corporate Update

November 09, 2026

Black Diamond Therapeutics to Host Webcast Highlighting Updated Silevertinib Phase 2 Data and FDA Feedback Supporting a Clear Phase 3 Path to Potential Accelerated Approval in 1L EGFR-NCM NSCLC

September 02, 2026

Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

August 05, 2026

Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

May 22, 2026

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 21, 2026

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

May 19, 2026

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

May 07, 2026

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

April 21, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

Displaying 1 - 10 of 12